The FDA continues to review clinical trial data to assess the possible association of mood and behavioral adverse effects related to medicines that affect the leukotriene pathway (montelukast [Singulair], zafirlukast [Accolate], and zileuton [Zyflo]). These medicines may also be used for allergic rhinitis and to prevent exercise-induced asthma. No conclusion has been reached, yet, but this update to the March release informs us that it may take another 9 months.
These medicines are effective in controlling your child's asthma. Please do not stop your child's medicine, but do speak to the pharmacist or doctor if there are any concerns. Monitor your child for any changes in behavior and mood that are untypical, including suicide thinking and behavior. Remember that the evaluation is ongoing, so there is nothing to panic about.
Tuesday, January 13, 2009
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment